Table 2.

Recommendations for Policymakers About Chagas Disease

Applied research
 Create multicenter/national database on chagasic patients
 Potentiate basic research and pathological studies about CD
 Potentiate the study of biomarkers associated with higher risk of chronic involvement in CD
 Perform epidemiological studies about CD by T cruzi strains and geographical areas
 Develop clinical trials about new, more effective and less toxic, trypanocide drugs. Explore combination of trypanocide drugs
 Develop consensus guidelines on diagnosis and treatment of CD
Clinical setting
 Screening for T cruzi among ischemic stroke patients from endemic regions
 Standardization of follow-up among chronic CD patients
 Active surveillance programs among asymptomatic T cruzi–infected patients
 Standardization of diagnostic serological and PCR techniques
 Development of prevention programs for chagasic stroke
 Detection of T cruzi drug resistance
Public health
 Develop a surveillance system to report detected cases of CD
 Measures to prevent congenital and blood T cruzi transmission. Compulsory serological tests in blood banks
 Develop active screening programs for T cruzi detection in stroke patients from endemic areas and their family members
 Potentiate awareness campaigns in the community, schools, and risk groups about CD
 Promote diagnosis, treatment, prevention, and rehabilitation strategies for CD in both endemic and nonendemic countries
 Training health workers and neurologists on early diagnose of CD and chagasic stroke
 Development of pre and postgraduation training programs in Tropical Neurology
  • CD indicates Chagas disease; PCR, polymerase chain reaction; and T cruzi, Trypanosome cruzi.